基质金属蛋白酶2和Ⅳ型胶原在肝细胞肝癌组织中的表达及意义

Expression and significance of MMP-2 and collagen Ⅳ protein in hepatocellular carcinoma

目的探讨基质金属蛋白酶2(MMP￣2)和Ⅳ型胶原在肝细胞肝癌(肝癌)患者的肝癌组织中表达及意义。方法本回顾性研究选择2005年1月至2007年12月广东省人民医院肝胆外科40例肝癌患者的肝切除标本(肝癌组)为研究对象,另取5例尸检来源的正常肝组织作为正常对照组,所有患者均签署知情同意书,符合医学伦理学规定。应用免疫组织化学方法检测其肝组织的MMP￣2和Ⅳ型胶原表达情况,用Spearman相关检验分析MMP￣2、IV型胶原与肝癌微血管浸润、肿瘤直径、分化程度、肿瘤复发的关系。结果 MMP￣2和Ⅳ型胶原在肝癌组的阳性表达分别为29例(73%)、38例(95%),MMP￣2在正常肝组织中无表达,Ⅳ型胶原在正常对照组中阳性表达为3例。MMP￣2和IV型胶原在肝癌组织表达率增高。MMP￣2和Ⅳ型胶原均与肝癌的复发有关(均为P<0.05),当有微血管浸润时,MMP￣2和Ⅳ型胶原的阳性率均显著增高(均为P<0.05)。结论 MMP￣2和Ⅳ型胶原在肝癌组织中呈阳性表达,且对判断肝癌患者术后复发有一定意义。

Objective To study the expression and significance of matrix metalloproteinase-2 （MMP- 2） and collagen Ⅳ protein （collagen Ⅳ ）in liver tissues of hepatoeellular carcinoma （HCC）. Methods Forty HCC tissues were collected from the hepatic resection speeieces in department of hepatic surgery in Guangdong General Hospital from Janaury 2005 to December 2007 and stained by immunohistochemistry to observe the expression of MMP-2 and collagen Ⅳ. Five normal liver tissues were obtained by autopsy as control. Local ethical committee approval had been received and that the informed concent of all participating subjects was obtained. The relationship between MMP-2, collagen Ⅳ expression and clinicopathologic features of HCC such as microvascular invasion, tumor diameter, tumor differentiation degree, recurrence was analyzed by test of Spearman＇s rank-correlation coefficient. Results The positive expression of MMP-2 and collagen Ⅳ in HCC tissues were 29 cases（73%） and 38 cases（95%） respectively. The MMP-2 expression was negative in normal liver tissues, while the expression of collagen Ⅳ was observed in 3 samples among 5 tested normal liver tissues. The expressions of MMP-2 and collagen Ⅳ were related to the recurrence of HCC （all in P〈0.05）. The positive expression rate of MMP-2 and collagen Ⅳ in HCC was markedly related to the microvascular invasion （all in P〈0.05）. Conclusions The expressions of MMP-2 and collagen Ⅳ are positive in HCC tissues and may relate to the recurrence of hepatocellular carcinoma.